EU industry: new PhV fee plan better, but still room for improvement
This article was originally published in SRA
Executive Summary
Groups representing the innovator and generic pharmaceutical industries in Europe have welcomed the changes the European Commission has made to its original plans for a pharmacovigilance fee system. However, there are still major problems with the proposal, they say.